CVR 35243798Private limited company (ApS)Ikke-finansielle holdingselskaber (642020)HolteFounded 15 May 2013
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about TENJ BIOTECH ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexResult
-16.2K
DKK, annual report 2019
Equity
145.2K
DKK, annual report 2019
TJ BIOTECH HOLDING ApSCVR 26415365, 100% of capital and votes, until 2 Dec 2020
Thomas Engelbrecht Nordkild Jonassenuntil 2 Dec 2020
No current owner is registered.
CVR 26415365100% of capital and votes15 May 2013 to 2 Dec 2020
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2019, DKK: Result for the year -16.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2019, DKK: Total assets 885.3K, Equity 145.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Result for the year | -14 | +3,352 | -16 | -1 | -16 |
| Equity | 27 | 179 | 163 | 161 | 145 |
| Total assets | 40 | 214 | 408 | 646 | 885 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for TENJ BIOTECH ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 80,000 | None | 80,000 | None | 80,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the ceasing company (ophørende selskab)
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
3 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Virksomheden er d. 02.12.2020 opløst ved fusion med CVR-nummer: 26415365 TJ BIOTECH HOLDING ApS.
Revision:
Fratrådte:
EY Godkendt Revisionspartnerselskab, den 17.09.2020.
Tiltrådte:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Værkmestergade 2, 18., 8000 Aarhus C, den 17.09.2020.
Stiftelsesdato:
15.05.2013.
Seneste vedtægtsdato:
15.05.2013.
Kapital:
kr. 80.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 80.000,00 til kurs 100,00.
Stifter:
CVR-NR. 26415365 TJ BIOTECH HOLDING ApS, Pile Alle 20, 2840 Holte, den 15.05.2013.
Direktion:
Thomas Engelbrecht Nordkild Jonassen, den 15.05.2013.
Selskabet tegnes af en direktør eller af den samlede direktion.
Revision:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Osvald Helmuths Vej 4, postboks 250, 2000 Frederiksberg, den 15.05.2013.
Første regnskabsår:
15.05.2013 - 31.12.2013.
Regnskabsår:
01.01 - 31.12.
P-number 1018495798Pile Alle 20, 2840 Holte